Low-dose CT for lung cancer screening: position paper from the Italian college of thoracic radiology.
Computed tomography
Computer assisted diagnosis
Early diagnosis
Lung cancer
Lung nodule
Screening
Journal
La Radiologia medica
ISSN: 1826-6983
Titre abrégé: Radiol Med
Pays: Italy
ID NLM: 0177625
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
received:
02
10
2021
accepted:
18
02
2022
pubmed:
21
3
2022
medline:
20
5
2022
entrez:
20
3
2022
Statut:
ppublish
Résumé
Smoking is the main risk factor for lung cancer (LC), which is the leading cause of cancer-related death worldwide. Independent randomized controlled trials, governmental and inter-governmental task forces, and meta-analyses established that LC screening (LCS) with chest low dose computed tomography (LDCT) decreases the mortality of LC in smokers and former smokers, compared to no-screening, especially in women. Accordingly, several Italian initiatives are offering LCS by LDCT and smoking cessation to about 10,000 high-risk subjects, supported by Private or Public Health Institutions, envisaging a possible population-based screening program. Because LDCT is the backbone of LCS, Italian radiologists with LCS expertise are presenting this position paper that encompasses recommendations for LDCT scan protocol and its reading. Moreover, fundamentals for classification of lung nodules and other findings at LDCT test are detailed along with international guidelines, from the European Society of Thoracic Imaging, the British Thoracic Society, and the American College of Radiology, for their reporting and management in LCS. The Italian College of Thoracic Radiologists produced this document to provide the basics for radiologists who plan to set up or to be involved in LCS, thus fostering homogenous evidence-based approach to the LDCT test over the Italian territory and warrant comparison and analyses throughout National and International practices.
Identifiants
pubmed: 35306638
doi: 10.1007/s11547-022-01471-y
pii: 10.1007/s11547-022-01471-y
pmc: PMC8934407
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
543-559Informations de copyright
© 2022. The Author(s).
Références
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424. https://doi.org/10.3322/caac.21492
doi: 10.3322/caac.21492
pubmed: 30207593
Passiglia F, Calandri M, Guerrera F, Malapelle U, Mangone L, Ramella S, Trisolini R, Novello S (2019) Lung Cancer in Italy. J Thorac Oncol Offic Publ Int Assoc Study Lung Cancer 14(12):2046–2052. https://doi.org/10.1016/j.jtho.2019.05.019
doi: 10.1016/j.jtho.2019.05.019
Pastorino U, Boffi R, Marchiano A, Sestini S, Munarini E, Calareso G, Boeri M, Pelosi G, Sozzi G, Silva M, Sverzellati N, Galeone C, La Vecchia C, Ghirardi A, Corrao G (2016) Stopping smoking reduces mortality in low-dose computed tomography screening participants. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer 11(5):693–699. https://doi.org/10.1016/j.jtho.2016.02.011
doi: 10.1016/j.jtho.2016.02.011
Tyczynski JE, Bray F, Parkin DM (2003) Lung cancer in Europe in 2000: epidemiology, prevention, and early detection. Lancet Oncol 4(1):45–55. https://doi.org/10.1016/s1470-2045(03)00960-4
doi: 10.1016/s1470-2045(03)00960-4
pubmed: 12517539
Force USPST, Krist AH, Davidson KW, Mangione CM, Barry MJ, Cabana M, Caughey AB, Davis EM, Donahue KE, Doubeni CA, Kubik M, Landefeld CS, Li L, Ogedegbe G, Owens DK, Pbert L, Silverstein M, Stevermer J, Tseng CW, Wong JB (2021) Screening for lung cancer: US preventive services task force recommendation statement. JAMA 325(10):962–970. https://doi.org/10.1001/jama.2021.1117
doi: 10.1001/jama.2021.1117
Su SY, Liaw YP, Jhuang JR, Hsu SY, Chiang CJ, Yang YW, Lee WC (2019) Associations between ambient air pollution and cancer incidence in Taiwan: an ecological study of geographical variations. BMC Public Health 19(1):1496. https://doi.org/10.1186/s12889-019-7849-z
doi: 10.1186/s12889-019-7849-z
pubmed: 31706295
pmcid: 6842529
Lipfert FW, Wyzga RE (2019) Longitudinal relationships between lung cancer mortality rates, smoking, and ambient air quality: a comprehensive review and analysis. Crit Rev Toxicol 49(9):790–818. https://doi.org/10.1080/10408444.2019.1700210
doi: 10.1080/10408444.2019.1700210
pubmed: 31985340
Lopatin S, Tsay JC, Addrizzo-Harris D, Munger JS, Pass H, Rom WN (2016) Reduced lung function in smokers in a lung cancer screening cohort with asbestos exposure and pleural plaques. Am J Ind Med 59(3):178–185. https://doi.org/10.1002/ajim.22571
doi: 10.1002/ajim.22571
pubmed: 26815630
Silva M, Sverzellati N, Colombi D, Milanese G, La Vecchia C, Galeone C, Marchiano A, Pastorino U (2017) Pleural plaques in lung cancer screening by low-dose computed tomography: prevalence, association with lung cancer and mortality. BMC Pulm Med 17(1):155. https://doi.org/10.1186/s12890-017-0506-3
doi: 10.1186/s12890-017-0506-3
pubmed: 29178853
pmcid: 5702182
Mastrangelo G, Marangi G, Ballarin MN, Fadda E, Scoizzato L, Fedeli U, Marchiori L, Valentini F (2016) Lung cancer risk in past asbestos workers a few decades after exposure cessation and prospects for screening. Arch Environ Occup Health 71(4):237–244. https://doi.org/10.1080/19338244.2015.1134423
doi: 10.1080/19338244.2015.1134423
pubmed: 26730642
National Lung Screening Trial Research T, Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM, Sicks JD (2011) Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 365(5):395–409. https://doi.org/10.1056/NEJMoa1102873
doi: 10.1056/NEJMoa1102873
Paci E, Puliti D, Lopes Pegna A, Carrozzi L, Picozzi G, Falaschi F, Pistelli F, Aquilini F, Ocello C, Zappa M, Carozzi FM, Mascalchi M, the IWG, (2017) Mortality, survival and incidence rates in the ITALUNG randomised lung cancer screening trial. Thorax. https://doi.org/10.1136/thoraxjnl-2016-209825
doi: 10.1136/thoraxjnl-2016-209825
pubmed: 28377492
Pastorino U, Silva M, Sestini S, Sabia F, Boeri M, Cantarutti A, Sverzellati N, Sozzi G, Corrao G, Marchiano A (2019) Prolonged lung cancer screening reduced 10-year mortality in the MILD trial: new confirmation of lung cancer screening efficacy. Ann Oncol Off J Eur Soc Med Oncol ESMO 30(7):1162–1169. https://doi.org/10.1093/annonc/mdz117
doi: 10.1093/annonc/mdz117
Becker N, Motsch E, Trotter A, Heussel CP, Dienemann H, Schnabel PA, Kauczor HU, Maldonado SG, Miller AB, Kaaks R, Delorme S (2020) Lung cancer mortality reduction by LDCT screening-results from the randomized German LUSI trial. Int J Cancer J Int du Cancer 146(6):1503–1513. https://doi.org/10.1002/ijc.32486
doi: 10.1002/ijc.32486
de Koning HJ, van der Aalst CM, de Jong PA, Scholten ET, Nackaerts K, Heuvelmans MA, Lammers JJ, Weenink C, Yousaf-Khan U, Horeweg N, van’t Westeinde S, Prokop M, Mali WP, Mohamed Hoesein FAA, van Ooijen PMA, Aerts J, den Bakker MA, Thunnissen E, Verschakelen J, Vliegenthart R, Walter JE, Ten Haaf K, Groen HJM, Oudkerk M (2020) Reduced lung-cancer mortality with volume CT screening in a randomized trial. N Engl J Med 382(6):503–513. https://doi.org/10.1056/NEJMoa1911793
doi: 10.1056/NEJMoa1911793
pubmed: 31995683
Passiglia F, Cinquini M, Bertolaccini L, Del Re M, Facchinetti F, Ferrara R, Franchina T, Larici AR, Malapelle U, Menis J, Passaro A, Pilotto S, Ramella S, Rossi G, Trisolini R, Novello S (2021) Benefits and harms of lung cancer screening by chest computed tomography: a systematic review and meta-analysis. J Clin Oncol Off J Am Soc Clin Oncol 39(23):2574–2585. https://doi.org/10.1200/JCO.20.02574
doi: 10.1200/JCO.20.02574
Puliti D, Picozzi G, Gorini G, Carrozzi L, Mascalchi M Gender effect in the ITALUNG screening trial. A comparison with UKLS and other trials. Lancet Reg Health Eur
Veronesi G, Maisonneuve P, Rampinelli C, Bertolotti R, Petrella F, Spaggiari L, Bellomi M (2013) Computed tomography screening for lung cancer: results of ten years of annual screening and validation of cosmos prediction model. Lung Cancer 82(3):426–430. https://doi.org/10.1016/j.lungcan.2013.08.026
doi: 10.1016/j.lungcan.2013.08.026
pubmed: 24099665
Pastorino U, Boeri M, Sestini S, Sabia F, Silva M, Suatoni P, Verri C, Cantarutti A, Sverzellati N, Corrao G, Marchiano A, Sozzi G (2019) Blood MicroRNA and LDCT Reduce Unnecessary LDCT Repeats in Lung Cancer Sreening: Results of Prospective bioMILD Trial. Paper presented at the World Congress of Lung Cancer, Barcelona (Spain), September 9, 2019
Pastorino U, Boeri M, Sestini S, Sabia F, Milanese G, Silva M, Suatoni P, Verri C, Cantarutti A, Sverzellati N, Corrao G, Marchianò A, Sozzi G (Accepted 2022) Blood microRNA and computed tomography predict lung cancer risk and define adequate screening intervals in the BioMILD trial. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO
OTCA28 – ‘Lung cancer screening in risk groups’ ( https://www.eunethta.eu/otca28/ ) (2020).
Mazzone PJ, Gould MK, Arenberg DA, Chen AC, Choi HK, Detterbeck FC, Farjah F, Fong KM, Iaccarino JM, Janes SM, Kanne JP, Kazerooni EA, MacMahon H, Naidich DP, Powell CA, Raoof S, Rivera MP, Tanner NT, Tanoue LK, Tremblay A, Vachani A, White CS, Wiener RS, Silvestri GA (2020) Management of lung nodules and lung cancer screening during the COVID-19 pandemic: CHEST expert panel report. Chest. https://doi.org/10.1016/j.chest.2020.04.020
doi: 10.1016/j.chest.2020.04.020
pubmed: 33171158
pmcid: 8640837
Milanese G, Sabia F, Sestini S, Ledda RE, Rolli L, Suatoni P, Sverzellati N, Sozzi G, Apolone G, Marchiano AV, Pastorino U (2021) Feasibility and safety of lung cancer screening and prevention program during the COVID-19 pandemic. Chest 160(1):e5–e7. https://doi.org/10.1016/j.chest.2021.02.072
doi: 10.1016/j.chest.2021.02.072
pubmed: 33745992
Bonney A, Malouf R, Marchal C, Manners D, Fong KM, Marshall HM, Irving LB, Manser R (2021) Low-dose computed tomography (LDCT) screening for lung cancer—related mortality (Protocol). Cochrane Datab Syst Rev. https://doi.org/10.1002/14651858.CD013829
doi: 10.1002/14651858.CD013829
Oudkerk M, Devaraj A, Vliegenthart R, Henzler T, Prosch H, Heussel CP, Bastarrika G, Sverzellati N, Mascalchi M, Delorme S, Baldwin DR, Callister ME, Becker N, Heuvelmans MA, Rzyman W, Infante MV, Pastorino U, Pedersen JH, Paci E, Duffy SW, de Koning H, Field JK (2017) European position statement on lung cancer screening. Lancet Oncol 18(12):e754–e766. https://doi.org/10.1016/S1470-2045(17)30861-6
doi: 10.1016/S1470-2045(17)30861-6
pubmed: 29208441
Kauczor H-U, Baird A-M, Blum TG, Bonomo L, Bostantzoglou C, Burghuber O, Čepická B, Comanescu A, Couraud S, Devaraj A, Jespersen V, Morozov S, Agmon IN, Peled N, Powell P, Prosch H, Ravara S, Rawlinson J, Revel M-P, Silva M, Snoeckx A, van Ginneken B, van Meerbeeck JP, Vardavas C, von Stackelberg O, Gaga M (2020) ESR/ERS statement paper on lung cancer screening. Eur Radiol. https://doi.org/10.1007/s00330-020-06727-7
doi: 10.1007/s00330-020-06727-7
pubmed: 32394278
pmcid: 7476988
Veronesi G, Baldwin DR, Henschke CI, Ghislandi S, Iavicoli S, Oudkerk M, De Koning HJ, Shemesh J, Field JK, Zulueta JJ, Horgan D, Fiestas Navarrete L, Infante MV, Novellis P, Murray RL, Peled N, Rampinelli C, Rocco G, Rzyman W, Scagliotti GV, Tammemagi MC, Bertolaccini L, Triphuridet N, Yip R, Rossi A, Senan S, Ferrante G, Brain K, van der Aalst C, Bonomo L, Consonni D, Van Meerbeeck JP, Maisonneuve P, Novello S, Devaraj A, Saghir Z, Pelosi G (2020) Recommendations for implementing lung cancer screening with low-dose computed tomography in Europe. Cancers (Basel). https://doi.org/10.3390/cancers12061672
doi: 10.3390/cancers12061672
Definizione e aggiornamento dei livelli essenziali di assistenza, di cui all'articolo 1, comma 7, del decreto legislativo 30 dicembre 1992, n. 502. (17A02015) (2017)
(ESTI) ESoTI (2019) Chest CT for Lung Cancer Screening: Technical Standards [ https://www.myesti.org/content-esti/uploads/ESTI-LCS-technical-standards_2019-06-14.pdf ].
(QIBA) QIBA (2018) QIBA Profile: Small Lung Nodule Volume Assessment and Monitoring in Low Dose CT Screening
Messerli M, Kluckert T, Knitel M, Walti S, Desbiolles L, Rengier F, Warschkow R, Bauer RW, Alkadhi H, Leschka S, Wildermuth S (2017) Ultralow dose CT for pulmonary nodule detection with chest x-ray equivalent dose—a prospective intra-individual comparative study. Eur Radiol 27(8):3290–3299. https://doi.org/10.1007/s00330-017-4739-6
doi: 10.1007/s00330-017-4739-6
pubmed: 28093625
Milanese G, Silva M, Frauenfelder T, Eberhard M, Sabia F, Martini C, Marchiano A, Prokop M, Sverzellati N, Pastorino U (2019) Comparison of ultra-low dose chest CT scanning protocols for the detection of pulmonary nodules: a phantom study. Tumori. https://doi.org/10.1177/0300891619847271
doi: 10.1177/0300891619847271
pubmed: 31041885
Huber A, Landau J, Ebner L, Butikofer Y, Leidolt L, Brela B, May M, Heverhagen J, Christe A (2016) Performance of ultralow-dose CT with iterative reconstruction in lung cancer screening: limiting radiation exposure to the equivalent of conventional chest X-ray imaging. Eur Radiol 26(10):3643–3652. https://doi.org/10.1007/s00330-015-4192-3
doi: 10.1007/s00330-015-4192-3
pubmed: 26813670
Schreuder A, Jacobs C, Lessmann N, Broeders MJ, Silva M, Isgum I, de Jong PA, Sverzellati N, Prokop M, Pastorino U, Schaefer-Prokop CM, van Ginneken B (2021) Combining pulmonary and cardiac computed tomography biomarkers for disease-specific risk modelling in lung cancer screening. Eur Respir J. https://doi.org/10.1183/13993003.03386-2020
doi: 10.1183/13993003.03386-2020
pubmed: 33574075
Heuvelmans MA, Vonder M, Rook M, Groen HJM, De Bock GH, Xie X, Ijzerman MJ, Vliegenthart R, Oudkerk M (2019) Screening for early lung cancer, chronic obstructive pulmonary disease, and cardiovascular disease (the big-3) using low-dose chest computed tomography: current evidence and technical considerations. J Thorac Imaging 34(3):160–169. https://doi.org/10.1097/RTI.0000000000000379
doi: 10.1097/RTI.0000000000000379
pubmed: 30550403
Bartlett EC, Desai SR, Padley S, Ridge C, Silva M, Milanese G, Ruggirello M, Pastorino U, Darby MJ, Devaraj A (2019) Lung cancer screening reporting feasibility and capacity: what is the current status? Paper presented at the British Society of Thoracic Imaging 2019, Edinburgh, United Kingdom, Nov 7, 2019
Hwang EJ, Goo JM, Kim HY, Yoon SH, Jin GY, Yi J, Kim Y (2021) Variability in interpretation of low-dose chest CT using computerized assessment in a nationwide lung cancer screening program: comparison of prospective reading at individual institutions and retrospective central reading. Eur Radiol 31(5):2845–2855. https://doi.org/10.1007/s00330-020-07424-1
doi: 10.1007/s00330-020-07424-1
pubmed: 33123794
Devaraj A, van Ginneken B, Nair A, Baldwin D (2017) Use of volumetry for lung nodule management: theory and practice. Radiology 284(3):630–644. https://doi.org/10.1148/radiol.2017151022
doi: 10.1148/radiol.2017151022
pubmed: 28825886
ESTI Lung Cancer Screening Certification Project. (2019). https://www.myesti.org/lungcancerscreeningcertificationproject/ . Accessed December 1 2021
Hansell DM, Bankier AA, MacMahon H, McLoud TC, Muller NL, Remy J (2008) Fleischner society: glossary of terms for thoracic imaging. Radiology 246(3):697–722. https://doi.org/10.1148/radiol.2462070712
doi: 10.1148/radiol.2462070712
pubmed: 18195376
Soo E, Edey AJ, Mak SM, Moser J, Mohammadi S, Rodrigues T, Duffy SW, Field JK, Baldwin DR, Nair A, Devaraj A (2019) Impact of choice of volumetry software and nodule management guidelines on recall rates in lung cancer screening. Eur J Radiol 120:108646. https://doi.org/10.1016/j.ejrad.2019.108646
doi: 10.1016/j.ejrad.2019.108646
pubmed: 31526892
(ACR) ACoR (2019) Lung-screening reporting and data system (LungRADS) Version 1.1 [ https://www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/Lung-Rads ]. https://www.acr.org/-/media/ACR/Files/RADS/Lung-RADS/LungRADSAssessmentCategoriesv1-1.pdf?la=en . Accessed July 5 2019
Chelala L, Hossain R, Kazerooni EA, Christensen JD, Dyer DS, White CS (2021) Lung-RADS version 1.1: challenges and a look ahead, from the AJR special series on radiology reporting and data systems. AJR Am J Roentgenol 216(6):1411–1422. https://doi.org/10.2214/AJR.20.24807
doi: 10.2214/AJR.20.24807
pubmed: 33470834
Christensen JD (2021) Tools for Tracking Nodule Follow-up in Lung Cancer Screening. Paper presented at the Radiology Society of North America (RSNA) Meeting, Chicago (IL), November 29, 2021
Okereke IC, Nishi S, Zhou J, Goodwin JS (2019) Trends in lung cancer screening in the United States, 2016–2017. J Thorac Dis 11(3):873–881. https://doi.org/10.21037/jtd.2019.01.105
doi: 10.21037/jtd.2019.01.105
pubmed: 31019776
pmcid: 6462682
Pinsky PF, Gierada DS, Black W, Munden R, Nath H, Aberle D, Kazerooni E (2015) Performance of lung-RADS in the national lung screening trial: a retrospective assessment. Ann Intern Med 162(7):485–491. https://doi.org/10.7326/M14-2086
doi: 10.7326/M14-2086
pubmed: 25664444
pmcid: 4705835
Silva M, Milanese G, Sestini S, Sabia F, Jacobs C, van Ginneken B, Prokop M, Schaefer-Prokop CM, Marchiano A, Sverzellati N, Pastorino U (2021) Lung cancer screening by nodule volume in Lung-RADS v1.1: negative baseline CT yields potential for increased screening interval. Eur Radiol 31(4):1956–1968. https://doi.org/10.1007/s00330-020-07275-w
doi: 10.1007/s00330-020-07275-w
pubmed: 32997182
Myers R, Mayo J, Atkar-Khattra S, Yuan R, Yee J, English J, Mcguire A, Grant K, Dewar L, Tammemagi M, Lam S (2021) Prospective Evaluation of the International Lung Screening Trial (ILST) Protocol for Management of First Screening LDCT. Paper presented at the World Conference on Lung Cancer (WCLC) 2021, Worldwide Virtual Event, September 12, 2021
Munden RF, Carter BW, Chiles C, MacMahon H, Black WC, Ko JP, McAdams HP, Rossi SE, Leung AN, Boiselle PM, Kent MS, Brown K, Dyer DS, Hartman TE, Goodman EM, Naidich DP, Kazerooni EA, Berland LL, Pandharipande PV (2018) Managing incidental findings on Thoracic CT: mediastinal and cardiovascular findings. A white paper of the ACR incidental findings committee. J Am Coll Radiol 15(8):1087–1096. https://doi.org/10.1016/j.jacr.2018.04.029
doi: 10.1016/j.jacr.2018.04.029
pubmed: 29941240
Munden RF, Black WC, Hartman TE, MacMahon H, Ko JP, Dyer DS, Naidich D, Rossi SE, McAdams HP, Goodman EM, Brown K, Kent M, Carter BW, Chiles C, Leung AN, Boiselle PM, Kazerooni EA, Berland LL, Pandharipande PV (2021) Managing incidental findings on thoracic CT: lung findings. A white paper of the ACR incidental findings committee. J Am Coll Radiol 18(9):1267–1279. https://doi.org/10.1016/j.jacr.2021.04.014
doi: 10.1016/j.jacr.2021.04.014
pubmed: 34246574
Callister ME, Baldwin DR, Akram AR, Barnard S, Cane P, Draffan J, Franks K, Gleeson F, Graham R, Malhotra P, Prokop M, Rodger K, Subesinghe M, Waller D, Woolhouse I, British Thoracic Society Pulmonary Nodule Guideline Development G, British Thoracic Society Standards of Care C (2015) British Thoracic Society guidelines for the investigation and management of pulmonary nodules. Thorax, doi: https://doi.org/10.1136/thoraxjnl-2015-207168
Creamer A, Dickson J, Horst C, Tisi S, Hall H, Verghese P, Mccabe J, Gyertson K, Mullin AM, Farrelly L, Clark C, Hamilton S, Allen B, Hackshaw A, Devaraj A, Nair A, Janes S (2021) Delayed interval scanning is not associated with stage-shift at diagnosis: Preliminary results to support guidelines for lung cancer screening during the COVID-19 pandemic. Paper presented at the European Respiratory Society (ERS) International Congress
McWilliams A, Tammemagi MC, Mayo JR, Roberts H, Liu G, Soghrati K, Yasufuku K, Martel S, Laberge F, Gingras M, Atkar-Khattra S, Berg CD, Evans K, Finley R, Yee J, English J, Nasute P, Goffin J, Puksa S, Stewart L, Tsai S, Johnston MR, Manos D, Nicholas G, Goss GD, Seely JM, Amjadi K, Tremblay A, Burrowes P, MacEachern P, Bhatia R, Tsao MS, Lam S (2013) Probability of cancer in pulmonary nodules detected on first screening CT. N Engl J Med 369(10):910–919. https://doi.org/10.1056/NEJMoa1214726
doi: 10.1056/NEJMoa1214726
pubmed: 24004118
pmcid: 3951177
Kastner J, Hossain R, Jeudy J, Dako F, Mehta V, Dalal S, Dharaiya E, White C (2021) Lung-RADS version 1.0 versus lung-RADS version 1.1: comparison of categories using nodules from the national lung screening trial. Radiology 300(1):199–206. https://doi.org/10.1148/radiol.2021203704
doi: 10.1148/radiol.2021203704
pubmed: 33944631
Chung K, Jacobs C, Scholten ET, Goo JM, Prosch H, Sverzellati N, Ciompi F, Mets OM, Gerke PK, Prokop M, van Ginneken B, Schaefer-Prokop CM (2017) Lung-RADS Category 4X: Does it improve prediction of malignancy in subsolid nodules? Radiology. https://doi.org/10.1148/radiol.2017161624
doi: 10.1148/radiol.2017161624
pubmed: 28640693
(ESTI) ESoTI (2019) Chest CT for Lung cancer screening: structured report basic template
Horst C, Dickson JL, Tisi S, Ruparel M, Nair A, Devaraj A, Janes SM (2020) Delivering low-dose CT screening for lung cancer: a pragmatic approach. Thorax 75(10):831–832. https://doi.org/10.1136/thoraxjnl-2020-215131
doi: 10.1136/thoraxjnl-2020-215131
pubmed: 32792406
Silva M, Prokop M, Jacobs C, Capretti G, Sverzellati N, Ciompi F, van Ginneken B, Schaefer-Prokop CM, Galeone C, Marchiano A, Pastorino U (2018) Long-term active surveillance of screening detected subsolid nodules is a safe strategy to reduce overtreatment. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. https://doi.org/10.1016/j.jtho.2018.06.013
doi: 10.1016/j.jtho.2018.06.013
Jonas DE, Reuland DS, Reddy SM, Nagle M, Clark SD, Weber RP, Enyioha C, Malo TL, Brenner AT, Armstrong C, Coker-Schwimmer M, Middleton JC, Voisin C, Harris RP (2021) Screening for lung cancer with low-dose computed tomography: updated evidence report and systematic review for the US preventive services task force. JAMA 325(10):971–987. https://doi.org/10.1001/jama.2021.0377
doi: 10.1001/jama.2021.0377
pubmed: 33687468
van de Wiel JC, Wang Y, Xu DM, van der Zaag-Loonen HJ, van der Jagt EJ, van Klaveren RJ, Oudkerk M, group Ns, (2007) Neglectable benefit of searching for incidental findings in the Dutch-Belgian lung cancer screening trial (NELSON) using low-dose multidetector CT. Eur Radiol 17(6):1474–1482. https://doi.org/10.1007/s00330-006-0532-7
doi: 10.1007/s00330-006-0532-7
pubmed: 17206426
Kucharczyk MJ, Menezes RJ, McGregor A, Paul NS, Roberts HC (2011) Assessing the impact of incidental findings in a lung cancer screening study by using low-dose computed tomography. Can Assoc Radiol J 62(2):141–145. https://doi.org/10.1016/j.carj.2010.02.008
doi: 10.1016/j.carj.2010.02.008
pubmed: 20382501
Puliti D, Mascalchi M, Carozzi FM, Carrozzi L, Falaschi F, Paci E, Lopes Pegna A, Aquilini F, Barchielli A, Bartolucci M, Grazzini M, Picozzi G, Pistelli F, Rosselli A, Zappa M, Group IW (2019) Decreased cardiovascular mortality in the ITALUNG lung cancer screening trial: Analysis of underlying factors. Lung cancer 138:72-78. doi: https://doi.org/10.1016/j.lungcan.2019.10.006
Quality Assurance Standards prepared for the Targeted Lung Health Checks Programme (2019). https://www.england.nhs.uk/wp-content/uploads/2019/02/targeted-screening-for-lung-cancer-quality-assurance-standard.pdf
Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC Jr, Sperling L, Virani SS, Yeboah J (2019) 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 73(24):e285–e350. https://doi.org/10.1016/j.jacc.2018.11.003
doi: 10.1016/j.jacc.2018.11.003
pubmed: 30423393
Shemesh J, Henschke CI, Shaham D, Yip R, Farooqi AO, Cham MD, McCauley DI, Chen M, Smith JP, Libby DM, Pasmantier MW, Yankelevitz DF (2010) Ordinal scoring of coronary artery calcifications on low-dose CT scans of the chest is predictive of death from cardiovascular disease. Radiology 257(2):541–548. https://doi.org/10.1148/radiol.10100383
doi: 10.1148/radiol.10100383
pubmed: 20829542
Sverzellati N, Cademartiri F, Bravi F, Martini C, Gira FA, Maffei E, Marchiano A, La Vecchia C, De Filippo M, Kuhnigk JM, Rossi C, Pastorino U (2012) Relationship and prognostic value of modified coronary artery calcium score, FEV1, and emphysema in lung cancer screening population: the MILD trial. Radiology 262(2):460–467. https://doi.org/10.1148/radiol.11110364
doi: 10.1148/radiol.11110364
pubmed: 22114241
Chiles C, Duan F, Gladish GW, Ravenel JG, Baginski SG, Snyder BS, DeMello S, Desjardins SS, Munden RF, Team NS (2015) Association of coronary artery calcification and mortality in the national lung screening trial: a comparison of three scoring methods. Radiology 276 (1):82-90. https://doi.org/10.1148/radiol.15142062
Mascalchi M, Puliti D, Romei C, Picozzi G, De Liperi A, Diciotti S, Bartolucci M, Grazzini M, Vannucchi L, Falaschi F, Pistelli F, Gorini G, Carozzi F, Rosselli A, Carrozzi L, Paci E, Zappa M (2021) Moderate-severe coronary calcification predicts long-term cardiovascular death in CT lung cancer screening: The ITALUNG trial. Eur J Radiol 145:110040. https://doi.org/10.1016/j.ejrad.2021.110040
doi: 10.1016/j.ejrad.2021.110040
pubmed: 34814037
Balata H, Blandin Knight S, Barber P, Colligan D, Crosbie EJ, Duerden R, Elton P, Evison M, Greaves M, Howells J, Irion K, Karunaratne D, Kirwan M, Macnab A, Mellor S, Miller C, Newton T, Novasio J, Sawyer R, Sharman A, Slevin K, Smith E, Taylor B, Taylor S, Tonge J, Walsham A, Waplington S, Whittaker J, Booton R, Crosbie PAJ (2018) Targeted lung cancer screening selects individuals at high risk of cardiovascular disease. Lung Cancer 124:148–153. https://doi.org/10.1016/j.lungcan.2018.08.006
doi: 10.1016/j.lungcan.2018.08.006
pubmed: 30268454
Ruparel M, Quaife SL, Dickson JL, Horst C, Burke S, Taylor M, Ahmed A, Shaw P, Soo MJ, Nair A, Devaraj A, O’Dowd EL, Bhowmik A, Navani N, Sennett K, Duffy SW, Baldwin DR, Sofat R, Patel RS, Hingorani A, Janes SM (2019) Evaluation of cardiovascular risk in a lung cancer screening cohort. Thorax 74(12):1140–1146. https://doi.org/10.1136/thoraxjnl-2018-212812
doi: 10.1136/thoraxjnl-2018-212812
pubmed: 31558626
Tailor TD, Chiles C, Yeboah J, Rivera MP, Tong BC, Schwartz FR, Benefield T, Lane LM, Stashko I, Thomas SM, Henderson LM (2021) Cardiovascular risk in the lung cancer screening population: a multicenter study evaluating the association between coronary artery calcification and preventive statin prescription. J Am Coll Radiol 18(9):1258–1266. https://doi.org/10.1016/j.jacr.2021.01.015
doi: 10.1016/j.jacr.2021.01.015
pubmed: 33640340
Zhu Y, Yip R, Shemesh J, Jirapatnakul AC, Yankelevitz DF, Henschke CI (2020) Combined aortic valve and coronary artery calcifications in lung cancer screening as predictors of death from cardiovascular disease. Eur Radiol 30(12):6847–6857. https://doi.org/10.1007/s00330-020-07049-4
doi: 10.1007/s00330-020-07049-4
pubmed: 32725329
Cavigli E, Camiciottoli G, Diciotti S, Orlandi I, Spinelli C, Meoni E, Grassi L, Farfalla C, Pistolesi M, Falaschi F, Mascalchi M (2009) Whole-lung densitometry versus visual assessment of emphysema. Eur Radiol 19(7):1686–1692. https://doi.org/10.1007/s00330-009-1320-y
doi: 10.1007/s00330-009-1320-y
pubmed: 19224221
Labaki WW, Xia M, Murray S, Hatt CR, Al-Abcha A, Ferrera MC, Meldrum CA, Keith LA, Galban CJ, Arenberg DA, Curtis JL, Martinez FJ, Kazerooni EA, Han MK (2021) Quantitative emphysema on low-dose CT imaging of the chest and risk of lung cancer and airflow obstruction: an analysis of the national lung screening trial. Chest 159(5):1812–1820. https://doi.org/10.1016/j.chest.2020.12.004
doi: 10.1016/j.chest.2020.12.004
pubmed: 33326807
Robbins HA, Berg CD, Cheung LC, Chaturvedi AK, Katki HA (2019) Identification of candidates for longer lung cancer screening intervals following a negative low-dose computed tomography result. J Natl Cancer Inst 111(9):996–999. https://doi.org/10.1093/jnci/djz041
doi: 10.1093/jnci/djz041
pubmed: 30976808
pmcid: 6748798
Ashraf H, Lo P, Shaker SB, de Bruijne M, Dirksen A, Tonnesen P, Dahlback M, Pedersen JH (2011) Short-term effect of changes in smoking behaviour on emphysema quantification by CT. Thorax 66(1):55–60. https://doi.org/10.1136/thx.2009.132688
doi: 10.1136/thx.2009.132688
pubmed: 20978026
Schreuder A, Jacobs C, Lessmann N, Broeders M, Silva M, Isgum I, de Jong P, van den Heuvel M, Sverzellati N, Prokop M, Pastorino U, Schaefer-Prokop C, van Ginneken B (In Press) Scan-based competing death risk model for reevaluating lung cancer computed tomography screening eligibility. Eur Respir J
Mascalchi M, Camiciottoli G, Diciotti S (2017) Lung densitometry: why, how and when. J Thorac Dis 9(9):3319–3345. https://doi.org/10.21037/jtd.2017.08.17
doi: 10.21037/jtd.2017.08.17
pubmed: 29221318
pmcid: 5708390
Gevenois PA, De Vuyst P, de Maertelaer V, Zanen J, Jacobovitz D, Cosio MG, Yernault JC (1996) Comparison of computed density and microscopic morphometry in pulmonary emphysema. Am J Respir Crit Care Med 154(1):187–192. https://doi.org/10.1164/ajrccm.154.1.8680679
doi: 10.1164/ajrccm.154.1.8680679
pubmed: 8680679
Lynch DA, Austin JH, Hogg JC, Grenier PA, Kauczor HU, Bankier AA, Barr RG, Colby TV, Galvin JR, Gevenois PA, Coxson HO, Hoffman EA, Newell JD Jr, Pistolesi M, Silverman EK, Crapo JD (2015) CT-Definable subtypes of chronic obstructive pulmonary disease: a statement of the fleischner society. Radiology 277(1):192–205. https://doi.org/10.1148/radiol.2015141579
doi: 10.1148/radiol.2015141579
pubmed: 25961632
Sverzellati N, Guerci L, Randi G, Calabro E, La Vecchia C, Marchiano A, Pesci A, Zompatori M, Pastorino U (2011) Interstitial lung diseases in a lung cancer screening trial. Eur Respir J 38(2):392–400. https://doi.org/10.1183/09031936.00201809
doi: 10.1183/09031936.00201809
pubmed: 21233262
Hatabu H, Hunninghake GM, Richeldi L, Brown KK, Wells AU, Remy-Jardin M, Verschakelen J, Nicholson AG, Beasley MB, Christiani DC, San Jose Estepar R, Seo JB, Johkoh T, Sverzellati N, Ryerson CJ, Graham Barr R, Goo JM, Austin JHM, Powell CA, Lee KS, Inoue Y, Lynch DA (2020) Interstitial lung abnormalities detected incidentally on CT: a position paper from the fleischner society. Lancet Respir Med 8(7):726–737. https://doi.org/10.1016/S2213-2600(20)30168-5
doi: 10.1016/S2213-2600(20)30168-5
pubmed: 32649920
pmcid: 7970441
Rampinelli C, Preda L, Maniglio M, Sirica L, Travaini LL, Veronesi G, Bellomi M (2011) Extrapulmonary malignancies detected at lung cancer screening. Radiology 261(1):293–299. https://doi.org/10.1148/radiol.11102231
doi: 10.1148/radiol.11102231
pubmed: 21828191
Nguyen XV, Davies L, Eastwood JD, Hoang JK (2017) Extrapulmonary findings and malignancies in participants screened with chest CT in the national lung screening trial. J Am Coll Radiol 14(3):324–330. https://doi.org/10.1016/j.jacr.2016.09.044
doi: 10.1016/j.jacr.2016.09.044
pubmed: 28259326
Yousaf-Khan U, van der Aalst C, de Jong PA, Heuvelmans M, Scholten E, Lammers JW, van Ooijen P, Nackaerts K, Weenink C, Groen H, Vliegenthart R, Ten Haaf K, Oudkerk M, de Koning H (2017) Final screening round of the NELSON lung cancer screening trial: the effect of a 2.5-year screening interval. Thorax 72(1):48–56. https://doi.org/10.1136/thoraxjnl-2016-208655
doi: 10.1136/thoraxjnl-2016-208655
pubmed: 27364640
Pastorino U, Sverzellati N, Sestini S, Silva M, Sabia F, Boeri M, Cantarutti A, Sozzi G, Corrao G, Marchiano A (2019) Ten-year results of the multicentric italian lung detection trial demonstrate the safety and efficacy of biennial lung cancer screening. Eur J Cancer 118:142–148. https://doi.org/10.1016/j.ejca.2019.06.009
doi: 10.1016/j.ejca.2019.06.009
pubmed: 31336289
pmcid: 6755135
Sverzellati N, Silva M, Calareso G, Galeone C, Marchiano A, Sestini S, Sozzi G, Pastorino U (2016) Low-dose computed tomography for lung cancer screening: comparison of performance between annual and biennial screen. Eur Radiol 26(11):3821–3829. https://doi.org/10.1007/s00330-016-4228-3
doi: 10.1007/s00330-016-4228-3
pubmed: 26868497
Ten Haaf K, van der Aalst CM, de Koning HJ, Kaaks R, Tammemagi MC (2021) Personalising lung cancer screening: an overview of risk-stratification opportunities and challenges. Int J Cancer J Int du Cancer 149(2):250–263. https://doi.org/10.1002/ijc.33578
doi: 10.1002/ijc.33578
Raji OY, Duffy SW, Agbaje OF, Baker SG, Christiani DC, Cassidy A, Field JK (2012) Predictive accuracy of the Liverpool Lung Project risk model for stratifying patients for computed tomography screening for lung cancer: a case-control and cohort validation study. Ann Intern Med 157(4):242–250. https://doi.org/10.7326/0003-4819-157-4-201208210-00004
doi: 10.7326/0003-4819-157-4-201208210-00004
pubmed: 22910935
pmcid: 3723683
Lebrett MB, Balata H, Evison M, Colligan D, Duerden R, Elton P, Greaves M, Howells J, Irion K, Karunaratne D, Lyons J, Mellor S, Myerscough A, Newton T, Sharman A, Smith E, Taylor B, Taylor S, Walsham A, Whittaker J, Barber PV, Tonge J, Robbins HA, Booton R, Crosbie PAJ (2020) Analysis of lung cancer risk model (PLCOM2012 and LLPv2) performance in a community-based lung cancer screening programme. Thorax 75(8):661–668. https://doi.org/10.1136/thoraxjnl-2020-214626
doi: 10.1136/thoraxjnl-2020-214626
pubmed: 32631933
O’Dowd EL, Ten Haaf K (2019) Lung cancer screening: enhancing risk stratification and minimising harms by incorporating information from screening results. Thorax 74(9):825–827. https://doi.org/10.1136/thoraxjnl-2019-213156
doi: 10.1136/thoraxjnl-2019-213156
pubmed: 31363021
Baldwin D, O’Dowd E, Ten Haaf K (2020) Targeted screening for lung cancer is here but who do we target and how? Thorax 75(8):617–618. https://doi.org/10.1136/thoraxjnl-2020-215156
doi: 10.1136/thoraxjnl-2020-215156
pubmed: 32631934
Patz EF Jr, Greco E, Gatsonis C, Pinsky P, Kramer BS, Aberle DR (2016) Lung cancer incidence and mortality in National Lung Screening Trial participants who underwent low-dose CT prevalence screening: a retrospective cohort analysis of a randomised, multicentre, diagnostic screening trial. Lancet Oncol 17(5):590–599. https://doi.org/10.1016/S1470-2045(15)00621-X
doi: 10.1016/S1470-2045(15)00621-X
pubmed: 27009070
pmcid: 5094059
Rampinelli C, De Marco P, Origgi D, Maisonneuve P, Casiraghi M, Veronesi G, Spaggiari L, Bellomi M (2017) Exposure to low dose computed tomography for lung cancer screening and risk of cancer: secondary analysis of trial data and risk-benefit analysis. BMJ 356:j347. https://doi.org/10.1136/bmj.j347
doi: 10.1136/bmj.j347
pubmed: 28179230
pmcid: 5421449
Robbins HA, Callister M, Sasieni P, Quaife SL, Cheung LC, Brennan P, Katki HA, Berg CD, Baldwin D, Johansson M (2019) Benefits and harms in the national lung screening trial: expected outcomes with a modern management protocol. Lancet Respir Med. https://doi.org/10.1016/S2213-2600(19)30136-5
doi: 10.1016/S2213-2600(19)30136-5
pubmed: 31076382
pmcid: 6992839
de Koning HJ, Meza R, Plevritis SK, ten Haaf K, Munshi VN, Jeon J, Erdogan SA, Kong CY, Han SS, van Rosmalen J, Choi SE, Pinsky PF, Berrington de Gonzalez A, Berg CD, Black WC, Tammemagi MC, Hazelton WD, Feuer EJ, McMahon PM (2014) Benefits and harms of computed tomography lung cancer screening strategies: a comparative modeling study for the U.S. Preventive services task force. Ann Intern Med 160(5):311–320. https://doi.org/10.7326/M13-2316
doi: 10.7326/M13-2316
pubmed: 24379002
pmcid: 4116741
Kauczor H-U, Baird A-M, Blum TG, Bonomo L, Bostantzoglou C, Burghuber O, Čepická B, Comanescu A, Couraud S, Devaraj A, Jespersen V, Morozov S, Nardi Agmon I, Peled N, Powell P, Prosch H, Ravara S, Rawlinson J, Revel M-P, Silva M, Snoeckx A, van Ginneken B, van Meerbeeck JP, Vardavas C, von Stackelberg O, Gaga M (2020) ESR/ERS statement paper on lung cancer screening. Eur Respir J 55(2):1900506. https://doi.org/10.1183/13993003.00506-2019
doi: 10.1183/13993003.00506-2019
pubmed: 32051182
Yip R, Li K, Liu L, Xu D, Tam K, Yankelevitz DF, Taioli E, Becker B, Henschke CI (2018) Controversies on lung cancers manifesting as part-solid nodules. Eur Radiol 28(2):747–759. https://doi.org/10.1007/s00330-017-4975-9
doi: 10.1007/s00330-017-4975-9
pubmed: 28835992
Bartlett EC, Silva M, Callister ME, Devaraj A (2021) False negative results in lung cancer screening—evidence and controversies. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. https://doi.org/10.1016/j.jtho.2021.01.1607
doi: 10.1016/j.jtho.2021.01.1607
Scholten ET, Horeweg N, de Koning HJ, Vliegenthart R, Oudkerk M, Mali WP, de Jong PA (2015) Computed tomographic characteristics of interval and post screen carcinomas in lung cancer screening. Eur Radiol 25(1):81–88. https://doi.org/10.1007/s00330-014-3394-4
doi: 10.1007/s00330-014-3394-4
pubmed: 25187382
Hestbech MS, Siersma V, Dirksen A, Pedersen JH, Brodersen J (2011) Participation bias in a randomised trial of screening for lung cancer. Lung Cancer 73(3):325–331. https://doi.org/10.1016/j.lungcan.2010.12.018
doi: 10.1016/j.lungcan.2010.12.018
pubmed: 21324544
Smith HB, Ward R, Frazier C, Angotti J, Tanner NT (2021) Guideline recommended lung cancer screening adherence is superior with centralized approach. Chest. https://doi.org/10.1016/j.chest.2021.09.002
doi: 10.1016/j.chest.2021.09.002
pubmed: 34801593
pmcid: 8438161